Brain zapping therapy could curb meth addiction in veterans
NCT ID NCT06578429
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether deep transcranial magnetic stimulation (dTMS) can help veterans with methamphetamine use disorder. Researchers will stimulate a brain region called the insula, which is involved in cravings and decision-making. Thirty veterans will receive either real or sham stimulation to see if it reduces meth use and changes brain activity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Deep Transcranial Magnetic Stimulation (dTMS) using the H4 coil
- What this could lead to
- If it works, this could point toward a non-drug treatment to help people reduce or stop methamphetamine use.
- What could go wrong
- This is a very small, early-stage trial with only 30 participants. It may not show a clear benefit, and results may not apply to non-veterans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion: * Must be within the age range of 25-75. * Participants must meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for moderate to severe MUD (≥4 diagnostic symptoms). * Participants must be able to obtain a Motor Threshold (MT), which will be determined during the screening process. * Participants must have an adequately stable condition and environment to enable attendance at scheduled clinic visits. * Participants must be able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participation in study procedures in English. * If participants are on a medication regimen for comorbid symptoms, that regimen will be stable for the duration of the study and patient will be willing to remain on this regimen during the treatment phase. * Participants must be fluent in English Exclusion criteria: * Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, ferromagnetic metal in the head and body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/object in the head and body within 30 cm of the treatment coil. * General medical condition, disease, or neurological disorder that interferes with the assessments or participation. * Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk. * Current substance abuse as determined by positive toxicology screen * Have a mass lesion, cerebral infarct, or other active CNS disease, including a seizure disorder. * A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study. * Severe impediment to vision, hearing and/or hand movement, as this is likely to interfere with the ability to follow study protocols. * Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness). * Taking benzodiazepines or neuroleptic medications, or any medication known to alter seizure threshold. * Acute or unstable chronic illness. * Current or lifetime history of bipolar disorder or psychosis. * Participation in another concurrent intervention-based clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Methamphetamine use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
VA Palo Alto Health Care System
RECRUITINGPalo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diabetes and Weight-Loss drug help people quit meth?
- Can methadone clinics double as meth treatment centers?
- Brain zaps aimed at craving center could help break meth addiction
- Brain zaps synced to brain waves may curb meth cravings
- Can a single psilocybin dose help break meth addiction?
- Can a psychedelic help break meth addiction in people with HIV?